Overview
This formulation combines BPC-157 and TB-500 in a single lyophilised vial at equal concentrations (5 mg each). Both compounds target complementary mechanisms in tissue repair, and their co-administration is a widely studied model for synergistic regenerative effects.
Rationale for Combination Research
- Complementary Mechanisms: BPC-157 acts primarily through the NO-system and VEGF upregulation; TB-500 targets actin dynamics and satellite cell activation. Together they address multiple phases of tissue repair simultaneously.
- Overlapping Angiogenic Targets: Both peptides independently promote angiogenesis and fibroblast activity, with research suggesting additive effects in musculoskeletal injury models.
- Connective Tissue Models: Particularly studied in tendon, ligament, and cartilage repair protocols where both vascularisation and structural matrix deposition are critical endpoints.
Specifications
- BPC-157 content: 5 mg (CAS 137525-51-0)
- TB-500 content: 5 mg (CAS 77591-33-4)
- Combined purity: ≥99% per component (HPLC verified)
- Form: Lyophilised powder blend
For in vitro laboratory research use only. Not for human or animal administration.
Reviews
There are no reviews yet.